Conventional Collagen Crosslinking in Young Keratoconus
NCT ID: NCT02008175
Last Updated: 2013-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
21 participants
INTERVENTIONAL
2012-01-31
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators intend to evaluate the effectiveness of conventional collagen cross linking in young patients diagnosed with keratoconus.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The major problems concerning keratoconus in young patients are;
1. Rapid rates of progression in young keratoconic corneas as compared to adults.
2. Poor biomechanical properties of young corneas.
3. Poor quality of vision, which predisposes to a very poor quality of life.
4. High rates of complications and failure post keratoplasty in young patients.
The investigators intend to evaluate the effectiveness of conventional collagen crosslinking in young patients with keratoconus with regards to keratometric indices and visual acuity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conventional CXL
Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/sq.cm with riboflavin and distilled water alternated every 2 minutes was used for the procedure.
Conventional CXL
Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (\<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Conventional CXL
Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (\<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed to have keratoconus at presentation and willing for follow - up at regular intervals post treatment.
Exclusion Criteria
* Any ocular condition predisposing towards poor vision (retinal , lens problems)
3 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vasan Eye Care Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr.ANAND PARTHASARATHY, Dr. Ramesh Hariharan
Dr. Anand Parthasarathy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr.Anand Parthasarathy
Role: PRINCIPAL_INVESTIGATOR
Vasan Eye Care Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vasan Eye Care Hospital
Chennai, Tamil Nadu, India
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vinciguerra P, Albe E, Frueh BE, Trazza S, Epstein D. Two-year corneal cross-linking results in patients younger than 18 years with documented progressive keratoconus. Am J Ophthalmol. 2012 Sep;154(3):520-6. doi: 10.1016/j.ajo.2012.03.020. Epub 2012 May 24.
Chatzis N, Hafezi F. Progression of keratoconus and efficacy of pediatric [corrected] corneal collagen cross-linking in children and adolescents. J Refract Surg. 2012 Nov;28(11):753-8. doi: 10.3928/1081597X-20121011-01.
Caporossi A, Mazzotta C, Baiocchi S, Caporossi T, Denaro R, Balestrazzi A. Riboflavin-UVA-induced corneal collagen cross-linking in pediatric patients. Cornea. 2012 Mar;31(3):227-31. doi: 10.1097/ico.0b013e31822159f6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PED_CXL
Identifier Type: -
Identifier Source: org_study_id